04 June 2021>: Original Paper
Coronavirus Disease 2019 and Kidney Transplantation in Saudi Arabia: Outcomes and Future Opportunities
Ali Alshaqaq 1ABCDEF* , Abdulnaser Al Abadi 1ACF , Abdulrahman Altheaby 2ABF , Mohammed A. Bukhari 3ABF , Basil Nasrallah 1AB , Alaa Alamoudi 4AB , Ziad Arabi 2A , Fayez Alhejaili 2B , Khalid Bin Saad 2A , Ahmed Busbaih 5B , Mohammed Abdelrahim Idris 1AB , Sumayah Askandarani 1AB , Meteb M. AlBugami 1A , Fahad E. Alotaibi 1E , Khaled Hamawi 1E , Khalid Bel’eed Akkari 1ACEDOI: 10.12659/AOT.931832
Ann Transplant 2021; 26:e931832
Table 3 Treatment and clinical outcomes.
Factors | Results (n=130) |
---|---|
Hydroxychloroquine | 15 (11.5%) |
Azithromycin | 40 (30.8%) |
Tocilizumab | 7 (5.4%) |
Favipiravir | 26 (20%) |
Convalescent serum or plasma | 7 (5.4%) |
Tacrolimus adjustment | 45 (34.6%) |
Mycophenolate adjustment | 115 (88.5%) |
Steroid adjustment | 100 (76.9%) |
28 (21.5%) | |
11 (7.25–24) | |
Nasal cannula | 16 (37.2%) |
High-flow nasal cannula | 8 (18.6%) |
Intubation/mechanical ventilation | 18 (41.9%) |
Extracorporeal membrane oxygenation | 1 (2.3%) |
14 (10.8%) | |
35 (26.9%) | |
8 (6.2%) | |
Bacterial | 29 (76.3%) |
Fungal | 3 (7.9%) |
Cytomegalovirus | 6 (15.8%) |
14 (10.8%) | |
** | 1 (0.77%) |
35 (29–44.25) | |
* Results are expressed as mean±standard deviation, median (25–75 percentile) and number (percentage); ** censored for death. |